Tao Synergies (TAOX) closed at $1.73 on November 18, 2026, down 7.5% from the previous close, on volume of 98,445 shares (30-day average 137,627).
Data as of November 18, 2026.
No press releases found.
Market Chameleon (Mon, 20-Oct 7:08 AM ET)
$11 Million Private Placement Reflects Confidence in TAOX's DeAI Strategy
Market Chameleon (Tue, 14-Oct 5:42 AM ET)
TAO Synergies Inc is mainly focused on developing a product platform based on its drug candidate, Bryostatin-1, for the treatment of Alzheimer's disease. The company is also evaluating Bryostatin-1 for other neurodegenerative and cognitive conditions, including Fragile X syndrome and Multiple Sclerosis, which have progressed through pre-clinical testing.
Tao Synergies trades on the NASDAQ stock market under the symbol TAOX.
As of November 19, 2026, TAOX stock price declined to $1.71 with 93,146 million shares trading.
TAOX has a beta of 0.72, meaning it tends to be less sensitive to market movements. TAOX has a correlation of 0.01 to the broad based SPY ETF.
TAOX has a market cap of $13.76 million. This is considered a Sub-Micro Cap stock.
The top ETF exchange traded funds that TAOX belongs to (by Net Assets): VXF, VTI, IWC, DFMC.
TAOX has underperformed the market in the last year with a price return of -76.0% while the SPY ETF gained +11.6%. TAOX has also underperformed the stock market ETF in the last 3 month and 2 week periods returning -46.9% and -36.0%, respectively, while the SPY returned -4.8% and -4.9%, respectively.
TAOX support price is $1.59 and resistance is $1.87 (based on 1 day standard deviation move). This means that using the most recent 20 day stock volatility and applying a one standard deviation move around the stock's closing price, stastically there is a 67% probability that TAOX shares will trade within this expected range on the day.